Researchers with the Hubrecht Institute in Utrecht, Netherlands and Radboud University in Nijmegen, Netherlands, developed a human model using organoids to evaluate the function of specific genes commonly mutated in liver cancer.
Pfizer Inc.’s experimental atopic dermatitis treatment abrocitinib met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease.
Akcea Therapeutics Inc. and Ionis Pharmaceuticals Inc. announced that Waylivra received conditional marketing authorization from the European Commission as the only therapy for FCS.
The acquisition of Abide Therapeutics Inc. will provide H. Lundbeck A/S with a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s syndrome.
First Digestive Enzyme Cartridge Designed for Patients on Enteral Feeding December 02, 2015 07:00 AM Eastern Standard Time NEWTON, Mass.–(BUSINESS WIRE)–Alcresta Pharmaceuticals, a specialty pharmaceutical company focused […]
BONITA, CA–(Marketwired – August 17, 2015) – PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company’s potentially game-changing pancreatic cancer treatment, and also as the […]
YONKERS, NY–(Marketwired – Aug 17, 2015) – ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody […]
